InBody

Founded in 1996, InBody is a medical device company specializing in body composition analyzers that use bioelectrical impedance technology to quantitatively measure muscle mass, body fat, and body water.

As of the first quarter of 2026, professional body composition analyzers and body water analyzers (BWA) accounted for 71.0% of total revenue, with consumer products such as home-use devices contributing 12.7% and software 3.6%.

The company operates 17 domestic and overseas subsidiaries and maintains a global distribution network through 13 overseas sales subsidiaries covering more than 100 countries.

Its customer base spans hospitals, obesity clinics, health screening centers, fitness centers, schools, and military units, and it has recently been expanding into pharmacies as a new sales channel.

In the domestic professional and mid-tier analyzer market, InBody holds a leading position, competing with a small number of players including Selvas Healthcare, which sells under the Accuniq brand.

Because overseas sales make up the large majority of revenue, the company has pursued a shift toward direct sales in key markets such as the United States, Japan, Europe, China, and Mexico.

This transition increased selling and administrative expense burden through subsidiary buildout and hiring, but continued revenue growth has gradually produced operating leverage.

More recently, InBody has been building a platform strategy that goes beyond hardware sales, leveraging its cumulative database of more than 200 million body composition measurements to connect with pharmacy consultation, chronic disease management, and digital healthcare services.

Annual revenue rose steadily from KRW 160.0 billion in 2022 to KRW 170.4 billion in 2023, KRW 204.5 billion in 2024, and KRW 233.9 billion in 2025.

Operating margin, however, declined for four consecutive years, from 25.4% in 2022 to 22.5% in 2023, 18.0% in 2024, and 15.7% in 2025, reflecting selling and administrative expenses tied to the shift toward direct overseas sales growing faster than revenue.

As a result, 2025 operating profit of KRW 36.75 billion was roughly flat versus 2024's KRW 36.74 billion, and net profit attributable to owners edged down from KRW 33.14 billion in 2024 to KRW 30.63 billion in 2025. The quarterly pattern tells a different story.

Operating margin was a relatively low 16.4% and 15.3% in the third and fourth quarters of 2025, respectively, before improving to about 19.0% in the first quarter of 2026 (revenue of KRW 68.4 billion, operating profit of KRW 13.0 billion) and rising further to roughly 24.2% in the second quarter of 2026 (revenue of KRW 73.3 billion, operating profit of KRW 17.7 billion).

Summing the most recent four quarters (Q3 2025 through Q2 2026) yields revenue of about KRW 263.9 billion and operating profit of about KRW 50.1 billion, both already exceeding full-year 2025 totals.

On the net income side, first-quarter 2026 net profit attributable to owners of KRW 16.3 billion exceeded that quarter's operating profit of KRW 13.0 billion, suggesting some non-operating item contributed to the result, and whether this pattern persists will require confirmation in coming quarters.

Taken together, the 2022-2025 annual figures alone show a clear margin-decline trend, but the first-half 2026 quarterly results mark a shift toward simultaneous revenue growth and margin recovery.

The body composition analyzer industry has grown globally on the back of rising obesity rates and increasing health awareness, and the spread of GLP-1 class obesity drugs has recently emerged as a new demand driver.

While GLP-1 drugs demonstrate substantial weight loss in clinical settings, they also introduce a new clinical challenge of muscle mass loss, which is expanding the need for body composition analysis that distinguishes fat from skeletal muscle beyond hospitals and health screening centers into fitness facilities and pharmacies.

InBody's China subsidiary has been selected as a key partner in a pharmacy-based weight management room project led by a global pharmaceutical company, supplying devices such as the InBody260S to chain pharmacies, and the company has expanded similar marketing efforts targeting hospitals and clinics in the United States and Latin America.

In the domestic market, InBody maintains a leading position in the professional and mid-tier analyzer segments, competing in a relatively concentrated landscape against a small number of players including Selvas Healthcare.

Many overseas regions still show low penetration rates, which is cited as room for further business growth, with revenue increasing fairly evenly across the United States, Europe, Mexico, Latin America, China, and Japan.

That said, the industry growth narrative is heavily tied to the expansion of the GLP-1 drug market, meaning that the pace of obesity drug adoption or changes in reimbursement policy could directly affect demand for body composition analyzers.

Marking its 30th anniversary in 2026, the company is pursuing expansion from a hardware seller into a platform business connecting data, pharmacies, obesity management, and digital healthcare.

In China, InBody has begun supplying the InBody260S through a pharmacy-based weight management room project led by a global pharmaceutical company, with hospital-use InBody770CH-N and InBody270 supply also planned.

In the United States, InBody's New York subsidiary has partnered with an obesity-drug-related pharmaceutical company to supply high-end professional analyzers to the local medical market, and the company plans to expand supply to hospitals and clinics in response to the launch of oral GLP-1 drugs and potential expansion of Medicare coverage.

Sangsangin Securities projected in a July 2026 report that InBody would sustain annual growth in the high-teens percentage range. IBK Securities stated in an early-September 2026 report that as the "quality of weight loss" becomes more important, expanding demand for body composition analyzers is inevitable.

Mirae Asset Securities has been reported as estimating an opportunity of roughly KRW 71.2 billion in China's DTP (direct-to-patient specialty pharmacy) market alone.

However, all of these projections depend heavily on the pace of GLP-1 obesity drug market expansion, and the speed and scale at which this translates into actual revenue will need to be confirmed sequentially through coming quarterly results.